Compare Five Below Inc (FIVE) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five Below Inc vs Recursion Pharmaceuticals Inc — how do they compare? Five Below Inc trades at $235.7 (market cap $13.01B), while Recursion Pharmaceuticals Inc trades at $3.32 (market cap $1.78B). The key difference: Five Below Inc is far larger — about 7.3× Recursion Pharmaceuticals Inc's market cap, and Five Below Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| FIVE | RXRX | |
|---|---|---|
Market Cap | $13.01B | $1.78B |
Sector | Consumer Staples | Health |
52-Week High | $247.71 | $6.79 |
52-Week Low | $131.94 | $2.84 |
Enterprise Value | $13.90B | $1.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five Below (FIVE) is trading at $244.37, up 5.73% with strong bullish momentum. The stock shows consistent earnings beats, with Q1 2026 EPS of $2.22 exceeding expectations of $1.77. Technical indicators signal bullish sentiment, supported by positive moving averages. Revenue growth remains solid, projected to reach $5.1B in 2026, though net margins have compressed from 9.78% in 2022 to 6.54% in 2025. Analyst consensus is strongly bullish with 62% buy ratings and a $252.36 price target.
FIVE presents a compelling growth story with expanding revenue and strong institutional support. However, elevated valuation multiples (P/E 30.79) and compressed profit margins pose risks. The stock's proximity to 52-week highs suggests limited near-term upside without significant catalysts. Execution on store expansion and margin improvement will be critical for sustained outperformance.
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
